The key figures of the veterinary medicine market

With turnover of 833 million euros in France in 2015 and 1.2 billion euros in exports, including 700 million for the European Union alone, France is the European leader for research and production of veterinary medicines and reagents, with over 6,700 employees, and the biggest therapeutic arsenal in Europe (2,700 marketing authorisations). This position is reinforced by the fact that 4 French companies (Merial, Virbac, Ceva, Vetoquinol) are in the world's top ten manufacturers of veterinary medicines and reagents.

At global level, our top three members, Zoetis, MSD Santé Animale (Merck & Co) and Merial (Sanofi) total over 50% of the sales. Half of the 39 members of the SIMV are small and medium-sized companies (with turnover of less than 1% of the market). The veterinary market includes the dynamic companion animals segment, driven by increasing investment from French people in the well-being of their pets (market share of 43.6%), and the food-producing animal segment which accounts for over one half of the market (51.7%). Finally, particular interest is given to horse-riding (the equine market share being 4.7%).



The economic model of the veterinary medicine industry has to take account of the large number of species of animals, requiring marketing authorisation application forms that are specific to the various species, in particular when the animals are raised for human consumption. The diversity of the species and of their specific pathologies tends to split this market up (17% of the medicines sold reach a turnover of less than 40,000 euros). The 10 to 12% share of turnover that is devoted by the veterinary medicines industry to R&D procures growth through innovation of up to 6% per year for it. Historical reasons (Pasteurian tradition, first veterinary schools, strong ties with the fabric of the human health industry which is also very powerful in France, etc.) and economic reasons related to the numbers of animals in France have made the French market the second-largest animal health market in the world: 41 million large food-producing animals (cattle, pigs, sheep, and goats), in addition to 301 million heads of poultry (chicken, turkeys, and guinea fowl, ducks), 10 million rabbits, and 800,000 horses, and not forgetting 7.4 million dogs and 11.4 million cats.

Finally, breaking down the market by main therapeutic class reveals a predominance of prevention of infectious diseases by using vaccines and metaphylactic measures (vaccines 22.3%, antiparasitics 18.3%, insecticides 13.8%) rather than by using curative treatments (antibiotics 11.2%, topical treatment products 8.4%).

Find our 2015 video here

Le SIMV est membre de